BRPI0919295A2 - 1h-benzimidazol-5-carboxamidas como agentes anti-inflamatórios. - Google Patents

1h-benzimidazol-5-carboxamidas como agentes anti-inflamatórios.

Info

Publication number: BRPI0919295A2
Authority: BR; Brazil
Prior art keywords: carboxamides; benzimidazole; inflammatory agents; inflammatory; agents
Prior art date: 2008-09-25

Application number

BRPI0919295A

Other languages

English (en)

Inventor

Dirk Stenkamp

Henning Priepke

Henri Doods

Juergen Mack

Kirsten Arndt

Klaus Klinder

Norbert Hauel

Raimund Kuelzer

Roland Pfau

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-09-25

Filing date

2009-09-25

Publication date

2015-12-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40344110&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0919295(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-09-25 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2015-12-15 Publication of BRPI0919295A2 publication Critical patent/BRPI0919295A2/pt

Links

FNLQDVXHDNFXIY-UHFFFAOYSA-N 3h-benzimidazole-5-carboxamide Chemical class NC(=O)C1=CC=C2NC=NC2=C1 FNLQDVXHDNFXIY-UHFFFAOYSA-N 0.000 title 1
229940121363 anti-inflammatory agent Drugs 0.000 title 1
239000002260 anti-inflammatory agent Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Orthopedic Medicine & Surgery (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Dermatology (AREA)
Communicable Diseases (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Gynecology & Obstetrics (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Obesity (AREA)
Ophthalmology & Optometry (AREA)

BRPI0919295A 2008-09-25 2009-09-25 1h-benzimidazol-5-carboxamidas como agentes anti-inflamatórios. BRPI0919295A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US9998708P	2008-09-25	2008-09-25
EP08165120		2008-09-25
PCT/EP2009/062421 WO2010034796A1 (en)	2008-09-25	2009-09-25	1h-benz imidazole-5-carboxamides as anti-inflammatory agents

Publications (1)

Publication Number	Publication Date
BRPI0919295A2 true BRPI0919295A2 (pt)	2015-12-15

Family

ID=40344110

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
BRPI0919738A BRPI0919738A2 (pt)	2008-09-25	2009-09-25	3h-imidazo[4,5-c] piridino-6-carboxamidas como agentes anti-inflamatórios
BRPI0919292A BRPI0919292A2 (pt)	2008-09-25	2009-09-25	3h-imidazo[4,5-b] piridina-6-carboxamidas como agentes anti-inflamatórios
BRPI0919295A BRPI0919295A2 (pt)	2008-09-25	2009-09-25	1h-benzimidazol-5-carboxamidas como agentes anti-inflamatórios.

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
BRPI0919738A BRPI0919738A2 (pt)	2008-09-25	2009-09-25	3h-imidazo[4,5-c] piridino-6-carboxamidas como agentes anti-inflamatórios
BRPI0919292A BRPI0919292A2 (pt)	2008-09-25	2009-09-25	3h-imidazo[4,5-b] piridina-6-carboxamidas como agentes anti-inflamatórios

Country Status (17)

Country	Link
US (4)	US8598190B2 (pt)
EP (4)	EP2334652A1 (pt)
JP (4)	JP5591807B2 (pt)
KR (4)	KR20110056533A (pt)
CN (4)	CN102164911A (pt)
AR (4)	AR073684A1 (pt)
AU (4)	AU2009295814A1 (pt)
BR (3)	BRPI0919738A2 (pt)
CA (4)	CA2737552A1 (pt)
IL (4)	IL211137A0 (pt)
MX (4)	MX2011002903A (pt)
NZ (4)	NZ591843A (pt)
RU (4)	RU2011116131A (pt)
TW (4)	TW201018684A (pt)
UY (1)	UY32138A (pt)
WO (4)	WO2010034796A1 (pt)
ZA (2)	ZA201101042B (pt)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20100250458A1 (en) *	2009-03-30	2010-09-30	Mspot, Inc.	Content based social networking system and method
UY32138A (es)	2008-09-25	2010-04-30	Boehringer Ingelheim Int	Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
CN102361857B (zh) *	2008-09-26	2015-09-16	默沙东公司	可用作抗糖尿病剂的环状苯并咪唑衍生物
UY32470A (es) *	2009-03-05	2010-10-29	Boehringer Ingelheim Int	Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
CN105853415A (zh)	2009-05-12	2016-08-17	罗马克实验室有限公司	卤代烷基杂芳基苯甲酰胺化合物
BRPI1014322A2 (pt)	2009-06-26	2015-08-25	Romark Lab Lc	Método para tratar infecção, e para interromper ou evitar a produção de partículas virais infecciosas, combinação, e, composição farmacêutica.
WO2011099832A2 (en) *	2010-02-12	2011-08-18	Crystalgenomics, Inc.	Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
US8586604B2 (en) *	2010-08-20	2013-11-19	Boehringer Ingelheim International Gmbh	Inhibitors of the microsomal prostaglandin E2 synthase-1
US8759537B2 (en)	2010-08-20	2014-06-24	Boehringer Ingelheim International Gmbh	3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
TW201305178A (zh)	2010-10-29	2013-02-01	Glenmark Pharmaceuticals Sa	作為ｍＰＧＥＳ－１抑制物的三環化合物
US8466186B2 (en) *	2010-12-10	2013-06-18	Boehringer Ingelheim International Gmbh	Compounds
UY33779A (es)	2010-12-10	2012-07-31	Boehringer Ingelheim Int	?2-(fenilamino)-1H-bencimidazol-5-carboxamidas novedosas?
US8486968B2 (en)	2010-12-10	2013-07-16	Boehringer Ingelheim International Gmbh	Compounds
AR084174A1 (es)	2010-12-21	2013-04-24	Lilly Co Eli	Compuestos de imidazol-2-benzamida utiles para el tratamiento de osteoartritis y una composicion farmaceutica
WO2012102937A2 (en) *	2011-01-25	2012-08-02	Irm Llc	Compounds that expand hematopoietic stem cells
CA2826649C (en) *	2011-02-25	2016-07-26	Merck Sharp & Dohme Corp.	Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
EP2495244A1 (en)	2011-03-02	2012-09-05	NovaSaid AB	Piperidinyl benzoimidazole derivatives as mPGEs-1 inhibitors
WO2013012848A1 (en)	2011-07-18	2013-01-24	Merck Patent Gmbh	Benzamides
WO2013038308A1 (en)	2011-09-15	2013-03-21	Glenmark Pharmaceuticals S.A.	SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS AS mPGES-1 INHIBITORS
WO2013072825A1 (en)	2011-11-16	2013-05-23	Glenmark Pharmaceuticals S.A.	Phtalazinone derivatives as mpegs -1 inhibitors
US9006257B2 (en)	2012-02-09	2015-04-14	Glenmark Pharmaceuticals S.A.	Bicyclic compounds as mPGES-1 inhibitors
WO2013153535A1 (en)	2012-04-13	2013-10-17	Glenmark Pharmaceuticals S.A.	TRICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS
CN103450329B (zh) *	2012-05-29	2015-05-27	首都医科大学	3h-咪唑并吡啶-6-甲酰氨基酸苄酯、其合成、抗肿瘤活性和应用
CA2874303C (en)	2012-06-11	2020-10-13	Ucb Biopharma Sprl	Tnf -alpha modulating benz imidazoles
TWI568722B (zh)	2012-06-15	2017-02-01	葛蘭馬克製藥公司	作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
CN103922999B (zh) *	2013-01-16	2016-05-04	上海医药工业研究院	一种达比加群酯中间体的制备方法及中间体化合物
US20140221335A1 (en) *	2013-02-06	2014-08-07	Boehringer Ingelheim International Gmbh	Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
CN104030977B (zh) *	2013-03-07	2016-05-04	上海医药工业研究院	一种达比加群酯中间体的制备方法
WO2014167444A1 (en)	2013-04-08	2014-10-16	Glenmark Pharmaceuticals S.A.	SUBSTITUTED BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS
CA2913785C (en) *	2013-06-25	2021-08-31	F. Hoffmann-La Roche Ag	Compounds for treating spinal muscular atrophy
CN103435554A (zh) *	2013-09-06	2013-12-11	中国药科大学	2-苯氨基苯并咪唑类化合物及其用途
WO2015059618A1 (en)	2013-10-22	2015-04-30	Glenmark Pharmaceuticals S.A.	SUBSTITUTED PYRIMIDINE COMPOUNDS AS mPGES-1 INHIBITORS
CN105980365B (zh)	2014-02-11	2019-06-21	拜耳医药股份公司	作为mIDH1抑制剂的苯并咪唑-2-胺
PE20170143A1 (es)	2014-02-11	2017-03-19	Bayer Pharma AG	Benzimidazol-2-aminas como inhibidores de midh1
WO2015166398A1 (en) *	2014-04-30	2015-11-05	Aurigene Discovery Technologies Limited	3h-imidazo[4,5-b]pyridine derivatives as dihydroorotate dehydrogenase inhibitors
CN105198959B (zh) *	2014-06-13	2018-09-07	首都医科大学	咪唑并吡啶-6-甲酰-Met-Glu(OBzl)2,其合成,活性和应用
CN105294829B (zh) *	2014-06-13	2018-07-27	首都医科大学	咪唑并吡啶-6-甲酰-氨基酸苄酯，其合成，活性及应用
CN105198960B (zh) *	2014-06-13	2018-10-19	首都医科大学	咪唑并吡啶-6-甲酰-Met-AA-OBzl,其合成,活性和应用
CN105254709A (zh) *	2014-07-10	2016-01-20	首都医科大学	咪唑并吡啶-6-甲酰-Met-AA-OBzl,其合成,活性和应用
CN105315325A (zh) *	2014-07-10	2016-02-10	首都医科大学	咪唑并吡啶-6-甲酰-Met-Arg(NO2)-OBzl,其合成,活性和应用
CN105315335A (zh) *	2014-07-10	2016-02-10	首都医科大学	咪唑并吡啶-6-甲酰-Met-Gln-OBzl,其合成,活性和应用
PT3174535T (pt)	2014-08-01	2019-05-27	Glenmark Pharmaceuticals Sa	Formulação nanoparticulada compreendendo um inibidor de mpges-1
JP6645695B2 (ja) *	2014-10-14	2020-02-14	中尾　洋一	イミダゾピリジンアミン化合物、その製造方法及び用途
JP6672288B2 (ja)	2014-10-23	2020-03-25	バイエル・ファルマ・アクティエンゲゼルシャフト	腫瘍の治療のためのｍｉｄｈ１阻害剤としての１−シクロヘキシル−２−フェニルアミノベンゾイミダゾール
US10138226B2 (en)	2014-10-23	2018-11-27	Bayer Pharma Aktiengesellschaft	Benzimidazol-2-amines as MIDH1 inhibitors
CN106146615B (zh) *	2015-03-23	2021-08-24	首都医科大学	咪唑并吡啶-6-甲酰-氨基酸苄酯，其合成，活性和应用
WO2016185279A1 (en)	2015-05-21	2016-11-24	Glaxosmithkline Intellectual Property Development Limited	Benzoimidazole derivatives as pad4 inhibitors
EP3303302B1 (en)	2015-06-08	2019-03-20	Bayer Pharma Aktiengesellschaft	N-menthylbenzimidazoles as midh1 inhibitors
CN107698660B (zh) *	2015-06-23	2021-06-08	首都医科大学	咪唑并吡啶-6-甲酰-Lys(Lys)-寡肽,其合成,活性和应用
CN108026052B (zh)	2015-07-16	2021-10-08	德国癌症研究公共权益基金会	作为mIDH1抑制剂的5-羟烷基苯并咪唑类
WO2017102091A1 (en)	2015-12-18	2017-06-22	Bayer Pharma Aktiengesellschaft	Heteroarylbenzimidazole compounds
WO2017207534A1 (en)	2016-06-03	2017-12-07	Bayer Pharma Aktiengesellschaft	Substituted heteroarylbenzimidazole compounds
CA3079483A1 (en)	2017-11-22	2019-05-31	Khondrion Ip B.V.	Compounds as mpges-1 inhibitors
CN110294751B (zh) *	2018-03-21	2020-11-20	湖南化工研究院有限公司	具生物活性的咪唑[4,5-b]并吡啶类化合物及其制备方法和应用
EP3876939A4 (en)	2018-11-07	2022-08-10	Dana-Farber Cancer Institute, Inc.	Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
WO2020097396A1 (en)	2018-11-07	2020-05-14	Dana-Farber Cancer Institute, Inc.	Benzimidazole derivatives and aza-benzimidazole derivatives as janus kinase 2 inhibitors and uses thereof
US12509455B2 (en)	2018-11-07	2025-12-30	Dana-Farber Cancer Institute, Inc.	Imidazopyridine derivatives and aza-imidazopyridine derivatives as Janus kinase 2 inhibitors and uses thereof
CN114245807B (zh)	2019-06-25	2025-05-02	吉利德科学公司	Flt3l-fc融合蛋白和使用方法
GB201910608D0 (en) *	2019-07-24	2019-09-04	Enterprise Therapeutics Ltd	Compounds
CA3156828A1 (en)	2019-10-03	2021-04-08	Dana-Farber Cancer Institute, Inc.	Tricyclic kinase inhibitors and uses thereof
PH12022550835A1 (en)	2019-10-18	2023-07-03	Forty Seven Inc	Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
NZ786589A (en)	2019-10-31	2025-03-28	Forty Seven Llc	Anti-cd47 and anti-cd20 based treatment of blood cancer
TWI778443B (zh)	2019-11-12	2022-09-21	美商基利科學股份有限公司	Mcl1抑制劑
US12195458B2 (en)	2019-12-02	2025-01-14	Storm Therapeutics Limited	Polyheterocyclic compounds as METTL3 inhibitors
CN115362003B (zh)	2019-12-24	2024-03-22	卡尔那生物科学株式会社	二酰基甘油激酶调节化合物
WO2021131549A1 (ja) *	2019-12-26	2021-07-01	セイカ株式会社	ジアミノビフェニル化合物の製造方法
CA3168146A1 (en)	2020-01-20	2021-07-29	Genzyme Corporation	Therapeutic tyrosine kinase inhibitors for relapsing multiple sclerosis (rms)
TWI890283B (zh)	2020-02-14	2025-07-11	美商基利科學股份有限公司	結合ccr8之抗體及融合蛋白及其用途
JP7564888B2 (ja)	2020-05-01	2024-10-09	ギリアードサイエンシーズ，インコーポレイテッド	Ｃｄ７３阻害性２，４－ジオキソピリミジン化合物
TW202204350A (zh)	2020-05-06	2022-02-01	美商雅捷可斯治療公司	作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑
CN114249694B (zh) *	2020-09-22	2025-06-17	浙江四维医药科技有限公司	一种特格拉赞中间体的制备方法
CA3201936A1 (en)	2020-12-10	2022-06-16	Minhua Chen	Crystal form of tolebrutinib and preparation method thereof
IL303834A (en)	2020-12-23	2023-08-01	Genzyme Corp	4-amino-3-(4-phenoxyphenyl)-1,3-dihydro-2H-imidazo[4,5-C]pyridin-2-one derivatives and their salts
EP4267574B1 (en)	2020-12-23	2025-04-23	Ajax Therapeutics, Inc.	6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
TW202302145A (zh)	2021-04-14	2023-01-16	美商基利科學股份有限公司	ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
WO2022245671A1 (en)	2021-05-18	2022-11-24	Gilead Sciences, Inc.	Methods of using flt3l-fc fusion proteins
CN117355531A (zh)	2021-06-23	2024-01-05	吉利德科学公司	二酰基甘油激酶调节化合物
JP7651018B2 (ja)	2021-06-23	2025-03-25	ギリアードサイエンシーズ，インコーポレイテッド	ジアシルグリセロールキナーゼ調節化合物
MX2023014762A (es)	2021-06-23	2024-01-15	Gilead Sciences Inc	Compuestos moduladores de diacilglicerol quinasa.
EP4359413A1 (en)	2021-06-23	2024-05-01	Gilead Sciences, Inc.	Diacylglyercol kinase modulating compounds
PE20241186A1 (es)	2021-10-29	2024-06-03	Gilead Sciences Inc	Compuestos de cd73
CA3234638A1 (en)	2021-11-09	2023-05-19	Ajax Therapeutics, Inc.	6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
US12162881B2 (en)	2021-11-09	2024-12-10	Ajax Therapeutics, Inc.	Forms and compositions of inhibitors of JAK2
CN118488948A (zh)	2021-12-22	2024-08-13	吉利德科学公司	Ikaros锌指家族降解剂及其用途
US20240124412A1 (en)	2021-12-22	2024-04-18	Gilead Sciences, Inc.	Ikaros zinc finger family degraders and uses thereof
CA3248911A1 (en)	2022-01-28	2023-08-03	Gilead Sciences, Inc.	POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE 7 INHIBITORS
PL4245756T3 (pl)	2022-03-17	2025-02-17	Gilead Sciences, Inc.	Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania
AU2023240346A1 (en)	2022-03-24	2024-09-19	Gilead Sciences, Inc.	Combination therapy for treating trop-2 expressing cancers
TWI876305B (zh)	2022-04-05	2025-03-11	美商基利科學股份有限公司	用於治療結腸直腸癌之組合療法
EP4511127A1 (en)	2022-04-21	2025-02-26	Gilead Sciences, Inc.	Kras g12d modulating compounds
WO2024006929A1 (en)	2022-07-01	2024-01-04	Gilead Sciences, Inc.	Cd73 compounds
US20260042743A1 (en) *	2022-08-01	2026-02-12	Council Of Scientific And Industrial Research	Substituted benzimidazoles for treating viral diseases
US20240091351A1 (en)	2022-09-21	2024-03-21	Gilead Sciences, Inc.	FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
EP4638436A1 (en)	2022-12-22	2025-10-29	Gilead Sciences, Inc.	Prmt5 inhibitors and uses thereof
CN116332779B (zh) *	2023-03-13	2025-06-10	苏州敬业医药化工有限公司	一种3,4-二氨基苯甲酸甲酯的制备方法
JPWO2024190888A1 (pt) *	2023-03-16	2024-09-19
WO2024215754A1 (en)	2023-04-11	2024-10-17	Gilead Sciences, Inc.	Kras modulating compounds
PE20260121A1 (es)	2023-04-21	2026-01-16	Gilead Sciences Inc	Inhibidores de prmt5 y usos de los mismos
JP2026522894A (ja)	2023-06-30	2026-07-09	ギリアードサイエンシーズ，インコーポレイテッド	Ｋｒａｓ調節化合物
CN121568935A (zh)	2023-07-26	2026-02-24	吉利德科学公司	Parp7抑制剂
AU2024297978A1 (en)	2023-07-26	2026-02-05	Gilead Sciences, Inc.	Parp7 inhibitors
US20250109147A1 (en)	2023-09-08	2025-04-03	Gilead Sciences, Inc.	Kras g12d modulating compounds
EP4774280A1 (en)	2023-09-08	2026-07-15	Gilead Sciences, Inc.	Kras g12d modulating compounds
WO2025096589A1 (en)	2023-11-03	2025-05-08	Gilead Sciences, Inc.	Prmt5 inhibitors and uses thereof
US20250230168A1 (en)	2023-12-22	2025-07-17	Gilead Sciences, Inc.	Azaspiro wrn inhibitors
WO2025245003A1 (en)	2024-05-21	2025-11-27	Gilead Sciences, Inc.	Prmt5 inhibitors and uses thereof
US20260098049A1 (en)	2024-08-12	2026-04-09	Gilead Sciences, Inc.	Kras modulating compounds
US20260130893A1 (en)	2024-10-21	2026-05-14	Gilead Sciences, Inc.	Prmt5 inhibitors and uses thereof
WO2026136515A1 (en)	2024-12-19	2026-06-25	Gilead Sciences, Inc.	Parp7 inhibitors
CN122213010A (zh) *	2026-05-20	2026-06-16	山东丰金制药有限公司	一种苏泽曲林中间体4-氨基吡啶-2-甲酸甲酯的制备方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3006671A1 (de)	1980-02-22	1981-08-27	Dr. Karl Thomae Gmbh, 7950 Biberach	Neue benzoxazole, deren herstellung und deren verwendung als arzneumittel
FI91859C (fi)	1987-06-17	1994-08-25	Eisai Co Ltd	Analogiamenetelmä antiallergisena aineena aktiivisen bentsotiatsolijohdannaisen valmistamiseksi
JPH06759B2 (ja)	1989-09-22	1994-01-05	ファイザー製薬株式会社	新規なベンゾイミダゾール化合物
PT1114028E (pt)	1998-08-26	2007-02-28	Aventis Pharma Ltd	Aza-biciclos moduladores da inibição da adesão celular
WO2000049005A1 (en)	1999-02-16	2000-08-24	Aventis Pharma Limited	Bicyclic compounds and their use as integrin receptor ligands
MXPA01010231A (es) *	1999-04-12	2003-07-21	Aventis Pharma Ltd	Compuestos heteroarilo biciclicos sustituidos como antagonistas de integrina.
ATE421958T1 (de) *	1999-05-05	2009-02-15	Aventis Pharma Ltd	Substituierte bizyclische verbindungen
US6340681B1 (en)	1999-07-16	2002-01-22	Pfizer Inc	2-benzimidazolylamine compounds as ORL-1-receptor agonists
DE60014130T2 (de)	1999-10-06	2006-03-09	Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield	Heterocyclische verbindungen verwendbar als tyrosinkinase inhibitoren
FR2833948B1 (fr)	2001-12-21	2004-02-06	Sod Conseils Rech Applic	Nouveaux derives de benzimidazole et leur utilisation en tant que medicament
CA2477505A1 (en)	2002-03-01	2003-09-12	Smithkline Beecham Corporation	Diamino-pyrimidines and their use as angiogenesis inhibitors
MXPA04009541A (es)	2002-03-29	2005-01-25	Chiron Corp	Benzazoles sustituidos y uso de los mismos como inhibidores de cinasa raf.
US7037902B2 (en)	2002-07-03	2006-05-02	Receptron, Inc.	Affinity small molecules for the EPO receptor
AU2003284142A1 (en)	2002-10-15	2004-05-04	Synta Pharmaceuticals Corp	Aromatic bicyclic heterocyles to modulate 1L-12 production
WO2004072068A1 (en)	2003-02-10	2004-08-26	Amgen Inc.	Vanilloid receptor ligands and their use in treatments
FR2851563B1 (fr)	2003-02-26	2005-04-22	Sod Conseils Rech Applic	Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
US7531553B2 (en)	2003-03-21	2009-05-12	Amgen Inc.	Heterocyclic compounds and methods of use
FR2852957B1 (fr)	2003-03-31	2005-06-10	Sod Conseils Rech Applic	Nouveaux derives d'imidazo-pyridine et leur utilisation en tant que medicament
US7329682B2 (en)	2003-04-03	2008-02-12	Ewha University-Industry Collaboration Foundation	Method for inhibiting 5-lipoxygenase using a benzoxazole derivative
US7714009B2 (en)	2003-10-31	2010-05-11	Takeda Pharmaceutical Company Limited	Nitrogen-containing fused heterocyclic compounds
GB0401334D0 (en)	2004-01-21	2004-02-25	Novartis Ag	Organic compounds
US7470712B2 (en) *	2004-01-21	2008-12-30	Bristol-Myers Squibb Company	Amino-benzazoles as P2Y1 receptor inhibitors
MXPA06014536A (es)	2004-06-18	2007-06-05	Biolipox Ab	Indoles utiles en el tratamiento de inflamacion.
US7723340B2 (en)	2005-01-13	2010-05-25	Signal Pharmaceuticals, Llc	Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7521446B2 (en) *	2005-01-13	2009-04-21	Signal Pharmaceuticals, Llc	Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
WO2006077366A1 (en) *	2005-01-19	2006-07-27	Biolipox Ab	Indoles useful in the treatment of inflammation
EP1877388A2 (en)	2005-02-25	2008-01-16	Kudos Pharmaceuticals Ltd	Hydrazinomethyl, hydrazonomethyl and 5-membered heterocylic compounds which act as mtor inhibitors and their use as anti cancer agents
US20060223849A1 (en) *	2005-03-14	2006-10-05	Mjalli Adnan M	Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors
JP2009515998A (ja) *	2005-11-16	2009-04-16	エスジーエックスファーマシューティカルズ、インコーポレイテッド	ピラゾロチアゾールタンパク質キナーゼモジュレータ
CN102633783A (zh)	2006-02-10	2012-08-15	转化技术制药公司	作为Aurora激酶抑制剂的苯并唑系衍生物、组合物和使用方法
US20070287344A1 (en) *	2006-06-12	2007-12-13	Hiroshi Ohara	Fabric Construction Specifically For Damper
WO2008009924A2 (en)	2006-07-18	2008-01-24	Biolipox Ab	Indoles useful in the treatment of inflammation
WO2008035956A1 (en)	2006-09-22	2008-03-27	Ewha University - Industry Collaboration Foundation	New benzoxazole derivative, process for the preparation thereof and pharmaceutical composition comprising the same
US20100004301A1 (en)	2006-12-14	2010-01-07	Benjamin Pelcman	Benzoxazoles Useful in the Treatment of Inflammation
WO2008129276A1 (en)	2007-04-19	2008-10-30	Boehringer Ingelheim International Gmbh	Disulfonamides useful in the treatment of inflammation
UY32138A (es)	2008-09-25	2010-04-30	Boehringer Ingelheim Int	Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
UY32470A (es)	2009-03-05	2010-10-29	Boehringer Ingelheim Int	Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
US8586604B2 (en)	2010-08-20	2013-11-19	Boehringer Ingelheim International Gmbh	Inhibitors of the microsomal prostaglandin E2 synthase-1
US8759537B2 (en)	2010-08-20	2014-06-24	Boehringer Ingelheim International Gmbh	3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
US8466186B2 (en)	2010-12-10	2013-06-18	Boehringer Ingelheim International Gmbh	Compounds
US8486968B2 (en)	2010-12-10	2013-07-16	Boehringer Ingelheim International Gmbh	Compounds
UY33779A (es)	2010-12-10	2012-07-31	Boehringer Ingelheim Int	?2-(fenilamino)-1H-bencimidazol-5-carboxamidas novedosas?

2009
- 2009-09-24 UY UY0001032138A patent/UY32138A/es not_active Application Discontinuation
- 2009-09-25 US US13/119,832 patent/US8598190B2/en not_active Expired - Fee Related
- 2009-09-25 WO PCT/EP2009/062421 patent/WO2010034796A1/en not_active Ceased
- 2009-09-25 MX MX2011002903A patent/MX2011002903A/es active IP Right Grant
- 2009-09-25 TW TW098132581A patent/TW201018684A/zh unknown
- 2009-09-25 US US13/119,834 patent/US8916599B2/en not_active Expired - Fee Related
- 2009-09-25 WO PCT/EP2009/062425 patent/WO2010034799A1/en not_active Ceased
- 2009-09-25 MX MX2011003094A patent/MX2011003094A/es not_active Application Discontinuation
- 2009-09-25 CN CN2009801376052A patent/CN102164911A/zh active Pending
- 2009-09-25 RU RU2011116131/04A patent/RU2011116131A/ru not_active Application Discontinuation
- 2009-09-25 CA CA2737552A patent/CA2737552A1/en not_active Abandoned
- 2009-09-25 EP EP09783402A patent/EP2334652A1/en not_active Withdrawn
- 2009-09-25 JP JP2011528330A patent/JP5591807B2/ja not_active Expired - Fee Related
- 2009-09-25 JP JP2011528331A patent/JP5591808B2/ja not_active Expired - Fee Related
- 2009-09-25 KR KR1020117006971A patent/KR20110056533A/ko not_active Withdrawn
- 2009-09-25 RU RU2011116129/04A patent/RU2011116129A/ru not_active Application Discontinuation
- 2009-09-25 BR BRPI0919738A patent/BRPI0919738A2/pt not_active IP Right Cessation
- 2009-09-25 AR ARP090103703A patent/AR073684A1/es unknown
- 2009-09-25 NZ NZ591843A patent/NZ591843A/xx not_active IP Right Cessation
- 2009-09-25 NZ NZ591847A patent/NZ591847A/xx not_active IP Right Cessation
- 2009-09-25 NZ NZ591845A patent/NZ591845A/xx not_active IP Right Cessation
- 2009-09-25 EP EP09783406.3A patent/EP2350073B1/en not_active Not-in-force
- 2009-09-25 MX MX2011003152A patent/MX2011003152A/es active IP Right Grant
- 2009-09-25 MX MX2011002948A patent/MX2011002948A/es active IP Right Grant
- 2009-09-25 CA CA2737384A patent/CA2737384A1/en not_active Abandoned
- 2009-09-25 JP JP2011528332A patent/JP5342646B2/ja not_active Expired - Fee Related
- 2009-09-25 CA CA2737839A patent/CA2737839A1/en not_active Abandoned
- 2009-09-25 US US13/119,836 patent/US8703796B2/en not_active Expired - Fee Related
- 2009-09-25 US US13/119,835 patent/US9040565B2/en not_active Expired - Fee Related
- 2009-09-25 TW TW098132579A patent/TW201016696A/zh unknown
- 2009-09-25 EP EP09783403A patent/EP2334664A1/en not_active Withdrawn
- 2009-09-25 CA CA2738083A patent/CA2738083A1/en not_active Abandoned
- 2009-09-25 CN CN2009801469428A patent/CN102224143A/zh active Pending
- 2009-09-25 CN CN2009801376014A patent/CN102164924A/zh active Pending
- 2009-09-25 AR ARP090103704A patent/AR073685A1/es unknown
- 2009-09-25 AU AU2009295814A patent/AU2009295814A1/en not_active Abandoned
- 2009-09-25 RU RU2011116133/04A patent/RU2011116133A/ru not_active Application Discontinuation
- 2009-09-25 BR BRPI0919292A patent/BRPI0919292A2/pt not_active IP Right Cessation
- 2009-09-25 NZ NZ591846A patent/NZ591846A/xx not_active IP Right Cessation
- 2009-09-25 AU AU2009295816A patent/AU2009295816A1/en not_active Abandoned
- 2009-09-25 KR KR1020117006974A patent/KR20110065478A/ko not_active Withdrawn
- 2009-09-25 KR KR1020117006846A patent/KR20110060910A/ko not_active Withdrawn
- 2009-09-25 TW TW098132551A patent/TW201018669A/zh unknown
- 2009-09-25 JP JP2011528333A patent/JP5342647B2/ja not_active Expired - Fee Related
- 2009-09-25 KR KR1020117006845A patent/KR20110056530A/ko not_active Withdrawn
- 2009-09-25 WO PCT/EP2009/062424 patent/WO2010034798A1/en not_active Ceased
- 2009-09-25 CN CN2009801371627A patent/CN102164922A/zh active Pending
- 2009-09-25 AR ARP090103705A patent/AR073686A1/es unknown
- 2009-09-25 WO PCT/EP2009/062422 patent/WO2010034797A1/en not_active Ceased
- 2009-09-25 RU RU2011116128/04A patent/RU2011116128A/ru not_active Application Discontinuation
- 2009-09-25 AR ARP090103706A patent/AR073403A1/es unknown
- 2009-09-25 AU AU2009295813A patent/AU2009295813A1/en not_active Abandoned
- 2009-09-25 EP EP09783405A patent/EP2361252A1/en not_active Withdrawn
- 2009-09-25 AU AU2009295815A patent/AU2009295815A1/en not_active Abandoned
- 2009-09-25 BR BRPI0919295A patent/BRPI0919295A2/pt not_active IP Right Cessation
- 2009-09-25 TW TW098132575A patent/TW201016682A/zh unknown
2011
- 2011-02-09 ZA ZA2011/01042A patent/ZA201101042B/en unknown
- 2011-02-09 IL IL211137A patent/IL211137A0/en unknown
- 2011-02-09 IL IL211138A patent/IL211138A0/en unknown
- 2011-02-09 ZA ZA2011/01041A patent/ZA201101041B/en unknown
- 2011-02-10 IL IL211148A patent/IL211148A0/en unknown
- 2011-02-10 IL IL211147A patent/IL211147A0/en unknown

Also Published As

Publication number	Publication date
TW201016682A (en)	2010-05-01
AR073403A1 (es)	2010-11-03
AU2009295814A1 (en)	2010-04-01
RU2011116129A (ru)	2012-10-27
US8703796B2 (en)	2014-04-22
CN102164922A (zh)	2011-08-24
AR073684A1 (es)	2010-11-24
AR073686A1 (es)	2010-11-24
US8598190B2 (en)	2013-12-03
JP5591808B2 (ja)	2014-09-17
CN102164911A (zh)	2011-08-24
IL211137A0 (en)	2011-04-28
IL211147A0 (en)	2011-04-28
KR20110065478A (ko)	2011-06-15
JP5342647B2 (ja)	2013-11-13
WO2010034797A1 (en)	2010-04-01
MX2011003152A (es)	2011-04-27
WO2010034798A1 (en)	2010-04-01
WO2010034799A1 (en)	2010-04-01
NZ591846A (en)	2012-11-30
IL211148A0 (en)	2011-04-28
TW201016696A (en)	2010-05-01
EP2334664A1 (en)	2011-06-22
IL211138A0 (en)	2011-04-28
JP5342646B2 (ja)	2013-11-13
JP2012503629A (ja)	2012-02-09
CA2737839A1 (en)	2010-04-01
TW201018684A (en)	2010-05-16
KR20110060910A (ko)	2011-06-08
KR20110056533A (ko)	2011-05-30
EP2350073A1 (en)	2011-08-03
TW201018669A (en)	2010-05-16
AU2009295813A1 (en)	2010-04-01
JP2012503628A (ja)	2012-02-09
JP2012503630A (ja)	2012-02-09
US8916599B2 (en)	2014-12-23
NZ591847A (en)	2013-01-25
JP5591807B2 (ja)	2014-09-17
BRPI0919738A2 (pt)	2015-12-08
MX2011002948A (es)	2011-04-26
ZA201101042B (en)	2011-10-26
CN102224143A (zh)	2011-10-19
RU2011116128A (ru)	2012-10-27
CA2737384A1 (en)	2010-04-01
US9040565B2 (en)	2015-05-26
RU2011116131A (ru)	2012-10-27
BRPI0919292A2 (pt)	2017-05-30
EP2361252A1 (en)	2011-08-31
CN102164924A (zh)	2011-08-24
RU2011116133A (ru)	2012-10-27
ZA201101041B (en)	2011-10-26
MX2011002903A (es)	2011-04-11
NZ591845A (en)	2012-10-26
MX2011003094A (es)	2011-04-26
CA2737552A1 (en)	2010-04-01
AU2009295815A1 (en)	2010-04-01
US20110312935A1 (en)	2011-12-22
EP2334652A1 (en)	2011-06-22
AU2009295816A1 (en)	2010-04-01
US20120122930A1 (en)	2012-05-17
KR20110056530A (ko)	2011-05-30
JP2012503627A (ja)	2012-02-09
US20120115902A1 (en)	2012-05-10
UY32138A (es)	2010-04-30
NZ591843A (en)	2012-09-28
AR073685A1 (es)	2010-11-24
WO2010034796A1 (en)	2010-04-01
CA2738083A1 (en)	2010-04-01
EP2350073B1 (en)	2014-11-12
US20110275656A1 (en)	2011-11-10

Legal Events

Date	Code	Title	Description
2016-06-07	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE AS 5A E 6A ANUIDADES.
2016-09-27	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2370 DE 07-06-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
BRPI1014956A2 (pt)	2018-07-24	agentes antinflamatórios.
NO2021006I1 (no)	2021-02-15	Quofenix, delafloksacin
BRPI1009315A2 (pt)	2016-03-08	agentes anti-inflamatórios
BRPI1010301A2 (pt)	2016-03-15	composição.
BRPI0913945A2 (pt)	2016-09-27	agentes anti-inflamatórios
BRPI0922845A2 (pt)	2015-12-29	pirazol-4-n-alcoxicarboxamidas como microbiocidas
BRPI0907376A2 (pt)	2015-07-14	Fotobiorretador
FIC20240018I1 (fi)	2024-06-04	Vamoroloni
BRPI0918430A2 (pt)	2015-11-24	4-fenil-1h-pirazóis inseticidas.
BRPI0908116A2 (pt)	2015-10-06	pulverizador
BRPI1008939A2 (pt)	2016-03-15	2-mercaptoquinolina-3-carboxamidas substituídas como moduladores de kncq2/3.
DK2259989T3 (da)	2013-02-04	Rem
UY33125A (es)	2011-07-29	Diaza-espiro-[5,5]-undecanos
EP2321062A4 (en)	2014-10-29	Sprayer
BRPI1011460A2 (pt)	2015-08-25	Composição desinfetante.
BRPI0917446A2 (pt)	2015-12-22	derivados de acilaminobenzamida.
BRPI0907522A2 (pt)	2019-09-24	biarlamidas
IT1396487B1 (it)	2012-12-14	Convogliatore.
BRPI0909634A2 (pt)	2015-09-22	2-aminoquinolinas
BRPI0907863A2 (pt)	2019-09-24	pirrolopirimidinacarboxamidas
AT507449A3 (de)	2010-11-15	Dämmstoffbefestiger
BRPI0916990A2 (pt)	2015-07-28	Combinações inseticidas
PT2277578T (pt)	2019-10-25	Nebulizador.
EP2309529A4 (en)	2015-06-03	PHOTO CATHODE
DK2254963T3 (da)	2012-09-17	Kerne-skal-flowforbedrer